Plasma drug activity assay for treatment optimization in tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5819-5825

  Heysell, Scott K ^a   Mtabho, Charles ^b   Mpagama, Stellah ^b,c   Mwaigwisya, Solomon ^b   Pholwat, Suporn ^a   Ndusilo, Norah ^b   Gratz, Jean ^a,b   Aarnoutse, Rob E ^d   Kibiki, Gibson S ^b   Houpt, Eric R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^c Kibong'oto National Tuberculosis Referral Hospital   (Tanzania)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TANZANIA; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG MONITORING; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TANZANIA; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 81555200436     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05561-11     Document Type: Article

References (32)

1. Caminero, J. A. 2006. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int. J. Tuberc. Lung Dis. 10:829-837. (Pubitemid 44197841)
2. Chang, K. C., et al. 2008. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis. 27:467-472.
3. Chideya, S., et al. 2009. Isoniazid, rifampin, ethambutol and pyrazinamide pharmacokinetics and treatment outcomes among predominately HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
4. Diacon, A. H., et al. 2010. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur. J. Clin. Microbiol. Infect. Dis. 29:1561-1565.
5. Diacon, A. H., et al. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996. (Pubitemid 47206244)
6. Dooley, K. E., and R. E. Chaisson. 2009. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9:737-746.
7. Espinal, M., and P. Farmer. 2009. The Cambridge Declaration: towards clinical trials for drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 13:1-2.
8. Gandhi, N. R., et al. 2010. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843.
9. Goutelle, S., et al. 2009. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53:2974-2981.
10. Hall, R. G., R. D. Leff, and T. Gumbo. 2009. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1468-1481.
11. Heysell, S. K., J. L. Moore, S. J. Keller, and E. R. Houpt. 2010. Therapeutic drug monitoring among slow responders to tuberculosis therapy in a state control program, Virginia, USA. Emerg. Infect. Dis. 16:1546-1553.
12. Holland, D. P., et al. 2009. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29:503-510.
13. Mehta, J. B., et al. 2001. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120:1520-1524. (Pubitemid 33078467)
14. Narita, M., et al. 2001. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin. Infect. Dis. 32:515-517. (Pubitemid 32173643)
15. Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. (Pubitemid 35252827)
16. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. (Pubitemid 29047048)
17. Pérez-Guzmán, C., M. H. Vargas, L. A. Martinez-Rossier, A. Torres-Cruz, and H. Villarreal-Velarde. 2002. Results of a 12-month regimen for drugresistant pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 6:1102-1109. (Pubitemid 36054965)
18. Pheiffer, C., et al. 2008. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int. J. Tuberc. Lung Dis. 12:792-798. (Pubitemid 351976711)
19. Reller, L. B., and C. W. Stratton. 1977. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J. Infect. Dis. 136:196-204. (Pubitemid 8170984)
20. Ruslami, R., et al. 2006. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 50:822-833.
21. Rylance, J., M. Pai, C. Lienhardt, and P. Garner. 2010. Priorities for tuberculosis research: a systematic review. Lancet Infect. Dis. 10:886-892.
22. Seifart, H. I., D. P. Parkin, F. J. Botha, P. R. Donald, and B. J. van der Walt. 2001. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol. Drug Saf. 10:127-134. (Pubitemid 32590943)
23. Srivastava, S., et al. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201:1225-1231.
24. van Ingen, J., et al. 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52:e194-e199.
25. Wallis, R. S., et al. 2001. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis. 183:1300-1303. (Pubitemid 32281574)
26. Wallis, R. S., et al. 2003. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J. Infect. Dis. 187:270-278. (Pubitemid 36132640)
27. Wallis, R. S., S. Vinhas, and E. Janulionis. 2009. Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis 89:221-224.
28. Weiner, M., et al. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167:1341-1347. (Pubitemid 36609717)
29. Weiner, M., et al. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491. (Pubitemid 40628637)
30. World Health Organization. 2009. (21 July 2010, accession date.) Global tuberculosis control: a short update to the 2009 report. http://www.who.int /tb/publications/global-report/2009/update/en/index.html. World Health Organization, Geneva, Switzerland.
31. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland.
32. Ziglam, H. M., D. R. Baldwin, I. Daniels, J. M. Andrew, and R. G. Finch. 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015.